Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 811 to 820 of 1447 total matches.
Indications for an Implantable Cardioverter Defibrillator
The Medical Letter on Drugs and Therapeutics • Nov 25, 2002 (Issue 1144)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 44 (W1144A ...
There is no longer any doubt that an implantable cardioverter defibrillator (ICD) can reliably terminate most life-threatening ventricular tachyarrhythmias. The remaining question is who should get one. Guidelines prepared by an American College of Cardiology/American Heart Association task force have recently been published (G Gregoratos et al, Circulation 2002; 106:2145).
Hemolysis From Ceftriaxone
The Medical Letter on Drugs and Therapeutics • Nov 25, 2002 (Issue 1144)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 44 (W1144B ...
Immune-mediated hemolysis is a rare adverse effect of second- and third-generation cephalosporins, especially cefotetan (Cefotan) (PA Arndt et al, Transfusion 1999; 39:1239). A recent report serves as a reminder that life-threatening immune-mediated hemolysis rarely can follow administration of ceftriaxone (Rocephin), one of the most commonly used parenteral antibiotics in the US (A Citak et al, J Paediatr Child Health 2002; 38:209).
Ibritumomab Tiuxetan (Zevalin) for Non-Hodgkin's Lymphoma
The Medical Letter on Drugs and Therapeutics • Nov 25, 2002 (Issue 1144)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 44 (W1144C ...
Yttrium-90 ibritumomab tiuxetan (Zevalin -IDEC) was approved by the FDA for treatment of patients with relapsed or refractory low-grade follicular or transformed B-cell non-Hodgkin's lymphoma (NHL), including patients with follicular lymphoma refractory to rituximab (Rituxan -Medical Letter 1998; 40:65). Zevalin is the first radioimmunoconjugate to be approved for treatment of cancer.
Valacyclovir (Valtrex) for Oral Herpes
The Medical Letter on Drugs and Therapeutics • Nov 11, 2002 (Issue 1143)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 44 (W1143A ...
Valacyclovir (Valtrex - GlaxoSmithKline) was recently approved by the FDA for one-day oral treatment of patients at least 12 years old with orolabial herpes simplex infections. The drug was previously approved for treatment and suppression of genital herpes and for treatment of herpes zoster (shingles).
Rasburicase (Elitek) for Hyperuricemia
The Medical Letter on Drugs and Therapeutics • Nov 11, 2002 (Issue 1143)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 44 (W1143B ...
Rasburicase (Elitek - Sanofi-Synthelabo), a recombinant form of urate oxidase derived from the fungus Aspergillus flavus, has been approved by the FDA for intravenous (IV) management of hyperuricemia associated with tumor lysis syndrome in pediatric patients.
Acetaminophen Safety
The Medical Letter on Drugs and Therapeutics • Oct 28, 2002 (Issue 1142)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 44 (W1142A ...
An FDA panel has recommended that stronger warnings about hepatotoxicity be added to the labeling for acetaminophen (www.fda.gov, search "acetaminophen hepatotoxicity").
Once-a-week Risedronate (Actonel)
The Medical Letter on Drugs and Therapeutics • Oct 14, 2002 (Issue 1141)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 44 (W1141A ...
A once-weekly 35-mg oral formulation of the bisphosphonate risedronate (Actonel) has been approved by the FDA for prevention and treatment of postmenopausal osteoporosis. A once-weekly formulation of alendronate (Fosamax) was approved last year (Medical Letter 2001; 43:26). Bisphosphonates bind to the mineral surface of bone and decrease osteoclast activity, inhibiting the resorption phase of the bone turnover cycle. These drugs are not metabolized and remain bound to bone for several weeks.
Beta Interferons for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Oct 14, 2002 (Issue 1141)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 44 (W1141B ...
Three beta interferons are widely used in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
Generic drugs
The Medical Letter on Drugs and Therapeutics • Oct 14, 2002 (Issue 1141)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 44 (W1141C ...
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the brand-name product?
Escitalopram (Lexapro) for Depression
The Medical Letter on Drugs and Therapeutics • Sep 30, 2002 (Issue 1140)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 44 (W1140A ...
Escitalopram (Lexapro - Forest), the active S-enantiomer of racemic citalopram (Celexa - Forest), a selective serotonin reuptake inhibitor (SSRI), was recently approved by the FDA for treatment of depression. The manufacturer plans to stop promoting Celexa in favor of Lexapro; Celexa will continue to be available for patients already taking it.